Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole Augmentation in Schizophrenia
NCT00325689Phase 4Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in schizophrenia and schizoaffective disorder comparing Aripiprazole Augmentation with Placebo Control (2 arms). Primary endpoint: Positive and Negative Symptoms Scale at 16 weeks. Started Jul 2006; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00325689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00325689.